本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Intellia Therapeutics Inc

11.37
+0.01960.17%
成交量:255.04万
成交额:2,936.96万
市值:12.21亿
市盈率:-2.43
高:11.80
开:11.17
低:11.06
收:11.36
52周最高:23.76
52周最低:5.90
股本:1.07亿
流通股本:1.02亿
量比:0.85
换手率:2.50%
股息:- -
股息率:- -
每股收益(TTM):-4.6831
每股收益(LYR):-5.2506
净资产收益率:-56.95%
总资产收益率:-30.62%
市净率:1.71
市盈率(LYR):-2.17

数据加载中...

公司资料

公司名字:
Intellia Therapeutics Inc
交易所:
NASDAQ
成立时间:
2014
员工人数:
403
公司地址:
40 Erie Street,Suite 130,Cambridge,Massachusetts,United States
邮编:
02139
电话:
传真:
- -
简介:
Intellia Therapeutics, Inc.于2014年5月在特拉华州注册成立。该公司是一家领先的基因编辑公司,专注于利用最近开发的被称为CRISPR/ Cas9的系统生物工具进行的独特的、潜在治愈疗法的发展。公司认为CRISPR/ Cas9技术具有通过单一疗程永久编辑疾病相关的基因在人体内进行改造药物的潜力。该公司打算利用其领先的科学专业知识、临床开发经验和知识产权地位解锁CRISPR/ Cas9基因编辑广泛的治疗应用,发展有潜能的新一代治疗产品。

董事

名称
职位
Frank Verwiel
Chairman of the Board
John M. Leonard
Director, President and Chief Executive Officer
Brian Goff
Independent Director
Fred Cohen
Independent Director
Georgia Keresty
Independent Director
Jesse Goodman
Independent Director
Muna Bhanji
Independent Director
William Chase
Independent Director

股东

名称
职位
John M. Leonard
Director, President and Chief Executive Officer
Edward J. Dulac, III
Treasurer, Executive Vice President and Chief Financial Officer
Birgit Schultes
Executive Vice President and Chief Scientific Officer
Eliana Clark
Executive Vice President and Chief Technology Officer
James Basta
Executive Vice President, General Counsel and Corporate Secretary
Michael P. Dube
Vice President and Chief Accounting Officer